Balyasny Asset Management’s Damora Therapeutics DMRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.7M Sell
973,000
-256,127
-21% -$7.24M 0.02% 759
2026
Q2
$32M Sell
1,229,127
-218,873
-15% -$5.3M 0.04% 513
2026
Q1
$37.5M Buy
+1,448,000
New +$37.2M 0.05% 441

Other funds holding DMRA

Balyasny Asset Management's DMRA Position: Q3 2026 in Review

Balyasny Asset Management reduced its Damora Therapeutics (DMRA) stake by 21% in Q3 2026, selling an estimated $7.24M and leaving 973,000 shares worth $20.7M. The position accounts for 0.02% of the portfolio, ranked #759.

Balyasny Asset Management first reported a position in DMRA in Q1 2026 and has held it in 3 quarters since. The position peaked at $37.5M in Q1 2026. 115 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

  • Balyasny Asset Management held 973,000 shares of Damora Therapeutics worth $20.7M as of Q3 2026.
  • Balyasny Asset Management sold 256,127 Damora Therapeutics shares in Q3 2026, an estimated $7.24M.
  • Damora Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q3 2026, its #759 holding.
  • Balyasny Asset Management first reported a position in Damora Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Balyasny Asset Management's Damora Therapeutics position peaked at $37.5M in Q1 2026.
  • 115 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on Balyasny Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.